RYLAZE: CLINICAL CONSIDERATIONS FOR AYA PATIENTS WITH ALL TREATED WITH ASPARAGINASE

Name: RYLAZE: CLINICAL CONSIDERATIONS FOR AYA PATIENTS WITH ALL TREATED WITH ASPARAGINASE
Start: 2024-10-29T18:00:00-05:00
Location: Bleu Duck Kitchen

Schedule

Tue Oct 29 2024 at 06:00 pm

UTC-05:00

Location

Bleu Duck Kitchen | Rochester, MN

Jazz Pharmaceuticals invites US healthcare professionals to a discussion on:
CLINICAL CONSIDERATIONS FOR AYA PATIENTS WITH ALL TREATED WITH ASPARAGINASE. A CASE-BASED REVIEW
Program topics:
• Factors that inform treatment decisions for patients with ALL
• The importance of asparaginase as a foundational component of ALL treatment
• The impact of hypersensitivity to E. coli-derived asparaginase on treatment outcomes in patients with ALL
• The clinical information about RYLAZE, including the study overview, efficacy data, safety profile, and two IM dosing options
RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen given by intramuscular injection for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Presented by: Julia Gourde, NP
Children's Hospital and Clinics of Minnesota
Date: October 29th, 2024
Time: 6:00 PM
Location: Bleu Duck Kitchen, 14 4th St SW, Rochester, MN, 55902
RSVP FOR THIS EVENT BY 10/22/24 by contacting Kristi Gauvin at:
[email protected] or 612-325-5829